郝伟,赵晨,胡思宁,贾海波,于波

• 1:哈尔滨医科大学附属第二医院心内科

摘要(Abstract)：

直接经皮冠状动脉介入治疗（PPCI）的广泛开展显著降低了急性ST段抬高型心肌梗死（STEMI）患者的死亡率。然而，有相当部分患者在冠状动脉重新开通后出现无复流（NR）现象，这严重限制了STEMI患者冠状动脉血运重建后的临床获益，并与患者的不良预后密切相关。本文主要就STEMI患者PPCI术后NR的诊断、病理机制、预测因素及其防治策略的最新研究成果及进展进行综述。

关键词(KeyWords)： 急性ST段抬高型心肌梗死;经皮冠状动脉介入治疗;无复流现象;微循环阻塞

Abstract:

Keywords:

基金项目(Foundation): 黑龙江省自然科学基金研究团队项目（TD2020H001）

作者(Author): 郝伟,赵晨,胡思宁,贾海波,于波

参考文献(References)：

• [1]马丽媛，王增武，樊静，等.《中国心血管健康与疾病报告2021》概要[J].中国介入心脏病学杂志，2022, 30(7):481-496. DOI:10.3969/j.issn.1004-8812.2022.07.001.
• [2] Caiazzo G, Musci RL, Frediani L, et al. State of the art:no-reflow phenomenon[J]. Cardiol Clin, 2020, 38(4):563-573. DOI:10.1016/j.ccl.2020.07.001.
• [3] Nishi T, Murai T, Ciccarelli G, et al. Prognostic value of coronary microvascular function measured immediately after percutaneous coronary intervention in stable coronary artery disease:an international multicenter study[J]. Circ Cardiovasc Interv, 2019, 12(9):e007889. DOI:10.1161/CIRCINTERVENTIONS.119.007889.
• [4] Papapostolou S, Andrianopoulos N, Duffy SJ, et al. Longterm clinical outcomes of transient and persistent no-reflow following percutaneous coronary intervention(PCI):a multicentre Australian registry[J]. EuroIntervention, 2018,14(2):185-193. DOI:10.4244/EIJ-D-17-00269.
• [5] Pantea-Ro?an LR, Bungau SG, Radu AF, et al. A narrative review of the classical and modern diagnostic methods of the noreflow phenomenon[J]. Diagnostics, 2022, 12(4):932.DOI:10.3390/diagnostics12040932.
• [6] Kelshiker MA,Seligman H,Howard JP, et al. Coronary flow reserve and cardiovascular outcomes:a systematic review and meta-analysis[J]. Eur Heart J,2022,43(16):1582-1593.DOI:10.1093/eurheartj/ehab775.
• [7] Fearon WF, Low AF, Yong AS, et al. Prognostic value of the index of microcirculatory resistance measured after primary percutaneous coronary intervention[J].Circulation, 2013, 127(24):2436-2441. DOI:10.1161/CIRCULATIONAHA.112.000298.
• [8]郑文，黄鑫，赵雪东.基于冠状动脉造影测定微循环阻力指数的研究进展[J].中国介入心脏病学杂志，2022, 30(6):448-451. DOI:10.3969/j.issn.1004-8812.2022.06.011.
• [9] de Waha S, Patel MR, Granger CB, et al. Relationship between microvascular obstruction and adverse events following primary percutaneous coronary intervention for ST-segment elevation myocardial infarction:an individual patient data pooled analysis from seven randomized trials[J]. Eur Heart J,2017, 38(47):3502-3510. DOI:10.1093/eurheartj/ehx414.
• [10] Mayr A, Klug G, Reindl M, et al. Evolution of myocardial tissue injury[J]. JACC Cardiovasc Imag, 2022, 15(6):1030-1042. DOI:10.1016/j.jcmg.2022.02.010.
• [11] Kaur G, Baghdasaryan P, Natarajan B, et al.Pathophysiology, diagnosis, and management of coronary noreflow phenomenon[J]. Int J Angiol, 2022, 31(2):107-112. DOI:10.1055/s-0041-1735949.
• [12] Zhao X, Han J, Zhou L, et al. High mobility group box 1 derived mainly from platelet microparticles exacerbates microvascular obstruction in no reflow[J]. Thromb Res, 2023, 222:49-62.DOI:10.1016/j.thromres.2022.12.003.
• [13] Mangold A, Ondracek AS, Hofbauer TM, et al. Culprit site extracellular DNA and microvascular obstruction in ST-elevation myocardial infarction[J]. Cardiovasc Res, 2022, 118(8):2006-2017. DOI:10.1093/cvr/cvab217.
• [14] Chen Y, Liu C, Zhou P, et al. Coronary endothelium noreflow injury is associated with ros-modified mitochondrial fission through the JNK-Drp1 signaling pathway[J]. Oxid Med Cell Longev, 2021, 2021:1-11. DOI:10.1155/2021/6699516.
• [15] Fajar JK, Heriansyah T, Rohman MS. The predictors of no reflow phenomenon after percutaneous coronary intervention in patients with ST elevation myocardial infarction:a metaanalysis[J]. Indian Heart J, 2018, 70:S406-S418. DOI:10.1016/j.ihj.2018.01.032.
• [16] Del Turco S, Basta G, De Caterina AR, et al. Different inflammatory profile in young and elderly STEMI patients undergoing primary percutaneous coronary intervention(PPCI):its influence on no-reflow and mortality[J]. Int J Cardiol, 2019,290:34-39. DOI:10.1016/j.ijcard.2019.05.002.
• [17] Gibbs T, Tapoulal N, Shanmuganathan M, et al.Neuropeptide-Y levels in ST-segment–elevation myocardial infarction:relationship with coronary microvascular function,heart failure, and mortality[J]. J Am Heart Assoc, 2022, 11(13):e024850. DOI:10.1161/JAHA.121.024850.
• [18] Zhao Y, Yang J, Ji Y, et al. Usefulness offibrinogento-albumin ratio to predict no-reflow and short-term prognosis in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention[J].Heart Vessels, 2019, 34(10):1600-1607. DOI:10.1007/s00380-019-01399-w.
• [19] Yildirim A, Kucukosmanoglu M, Koyunsever NY, et al.Relationship between blood viscosity and no-reflow phenomenon in ST-segment elevation myocardial infarction performed in primary percutaneous coronary interventions[J]. Biomarkers in Medicine, 2021, 15(9):659-667. DOI:10.2217/bmm-2020-0772.
• [20] Ko?uch M, Po?udniewski M, D?browski EJ, et al.Growth differentiation factor 15 as a predictor of the no-reflow phenomenon in patients with ST-segment elevation myocardial infarction[J]. J Clin Med, 2022, 12(1):245. DOI:10.3390/jcm12010245.
• [21] Mo DG, Wang CS, Liu JH, et al. The predictive value of eosinophil levels on no-reflow in patients with STEMI following PCI:a retrospective cohort study[J]. Sci Rep, 2022, 12(1):17862. DOI:10.1038/s41598-022-22988-2.
• [22] Hu CK, Cai RP, He L, et al. A nomogram model for predicting the occurrence of no-reflow phenomenon after percutaneous coronary intervention using the lncRNA TUG1/miR-30e/NPPB biomarkers[J]. J Thorac Dis, 2022, 14(6):2158-2168. DOI:10.21037/jtd-22-481.
• [23] Ciofani JL, Allahwala UK, Scarsini R, et al. No-reflow phenomenon in ST-segment elevation myocardial infarction:still the Achilles’ heel of the interventionalist[J]. Future Cardiology,2021, 17(2):383-397. DOI:10.2217/fca-2020-0077.
• [24] Soeda T, Higuma T, Abe N, et al. Morphological predictors for no reflow phenomenon after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction caused by plaque rupture[J]. Eur Heart J Cardiovasc Imaging, 2017, 18(1):103-110. DOI:10.1093/ehjci/jev341.
• [25] Terada K, Kubo T, Madder R, et al. Near-infrared spectroscopy to predict microvascular obstruction after primary percutaneous coronary intervention[J]. EuroIntervention, 2021, 17(12):e999-e1006. DOI:10.4244/EIJ-D-20-01421.
• [26] Kumar D, Ahmed I, Bardooli F, et al. Techniques to treat slow-flow/no-reflow during primary percutaneous coronary intervention[J]. Cardiovasc Revasc Med, 2023, 47:1-4.DOI:10.1016/j.carrev.2022.09.014.
• [27] Zhao S, Qi G, Tian W, et al. Effect of intracoronary nitroprusside in preventing no reflow phenomenon during primary percutaneous coronary intervention:a Meta-analysis:effect of intracoronary nitroprusside in preventing no reflow phenomenon[J]. J Int Cardiol, 2014, 27(4):356-364.DOI:10.1111/joic.12133.
• [28] Geng N, Ren L, Xu L, et al. Clinical outcomes of nicorandil administration in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention:a systematic review and meta-analysis of randomized controlled trials[J]. Bmc Cardiovasc Disor,2021, 21(1):488. DOI:10.1186/s12872-021-02301-1.
• [29] Laborante R,Bianchini E,Restivo A,et al. Adenosine as adjunctive therapy in acute coronary syndrome:a meta-analysis of randomized controlled trials[J]. Eur Heart J Cardiovasc Pharmacother,2023,9(2):173-182. DOI:10.1093/ehjcvp/pvac069.
• [30] Forman MB, Brewer EC, Brown ZR, et al. Novel guidewire design and coating for continuous delivery of adenosine during interventional procedures[J]. J Am Heart Assoc, 2021, 10(3):e019275. DOI:10.1161/JAHA.120.019275.
• [31] Wang H, Feng M. Influences of different dose of tirofiban for acute ST elevation myocardial infarction patients underwent percutaneous coronary intervention[J]. Medicine, 2020, 99(23):e20402. DOI:10.1097/MD.0000000000020402.
• [32] Tang X, Li R, Zhang T. Comparison of intracoronary versus intravenous tirofiban in acute ST-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention[J].Coronary Artery Disease, 2022, 33(7):547-552. DOI:10.1097/MCA.0000000000001177.
• [33] Hu X, Wang W, Ye J, et al. Effect of GPⅡb/Ⅲa inhibitor duration on the clinical prognosis of primary percutaneous coronary intervention in ST-segment elevation myocardial infarction with no-/slow-reflow phenomenon[J]. Biomed Pharmacother, 2021, 143:112196. DOI:10.1016/j.biopha.2021.112196.
• [34] Zeng Q,Zhang LD,Wang W. A meta-analysis of randomized controlled trials investigating tirofiban combined with conventional drugs by intracoronary administration for no-reflow prevention[J]. Anatol J Cardiol,2021,25(1):7-16.DOI:10.14744/AnatolJCardiol.2020.99469.
• [35] Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI guidelinefor coronary artery revascularization[J]. J Am Coll Cardiol, 2022, 79(2):e21-e129. DOI:10.1016/j.jacc.2021.09.006.
• [36] Chen L, Shi L, Tian W, et al. Intracoronary thrombolysis in patients with st-segment elevation myocardial infarction:a meta-analysis of randomized controlled trials[J]. Angiology,2021, 72(7):679-686. DOI:10.1177/0003319721995039.
• [37] Alyamani M, Campbell S, Navarese E, et al. Safety and efficacy of intracoronary thrombolysis as adjunctive therapy to primary PCI in STEMI:a systematic review and Meta-analysis[J].Can J Cardiol, 2021, 37(2):339-346. DOI:10.1016/j.cjca.2020.03.034.
• [38] McCartney PJ, Eteiba H, Maznyczka AM, et al. Effect of lowdose intracoronary alteplase during primary percutaneous coronary intervention on microvascular obstruction in patients with acute myocardial infarction:a randomized clinical trial[J]. JAMA,2019, 321(1):56. DOI:10.1001/jama.2018.19802.
• [39] McCartney PJ, Maznyczka AM, Eteiba H, et al. Lowdose alteplase during primary percutaneous coronary intervention according to ischemic time[J]. J Am Coll Cardiol, 2020, 75(12):1406-1421. DOI:10.1016/j.jacc.2020.01.041.
• [40] Aguiar MOD, Tavares BG, Tsutsui JM, et al. Sonothrombolysis improves myocardial dynamics and microvascular obstruction preventing left ventricular remodeling in patients with st elevation myocardial infarction[J]. Circ-Cardiovasc Imag, 2020, 13(4):e009536. DOI:10.1161/CIRCIMAGING.119.009536.
• [41] Kim JS, Kim J, Choi D, et al. Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in st-segment elevation myocardial infarction[J]. JACC Cardiovasc Interv, 2010, 3(3):332-339. DOI:10.1016/j.jcin.2009.11.021.
• [42] Li Q, Zhao YG, Wang Z, et al. Effects offirst highdose atorvastatin loading in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention[J]. Am J Therap, 2018, 25(3):e291-e298.DOI:10.1097/MJT.0000000000000370.
• [43] Navarese EP, Frediani L, Kandzari DE, et al. Efficacy and safety of intracoronary epinephrine versus conventional treatments alone in STEMI patients with refractory coronary no-reflow during primary PCI:The RESTOREobservational study[J].Catheter Cardiovasc Interv, 2021, 97(4):602-611. DOI:10.1002/ccd.29113.
• [44] Khan KA, Qamar N, Saghir T, et al. Comparison of intracoronary epinephrine and adenosinefor no-reflow in normotensive patients with acute coronary syndrome(COAR Trial)[J]. Circ Cardiovasc Interv, 2022, 15(2):e011408. DOI:10.1161/CIRCINTERVENTIONS.121.011408.
• [45] Saad M,Meyer-Saraei R,de Waha-Thiele S,et al.Impact of morphine treatment with and without metoclopramide coadministration on ticagrelor-induced platelet inhibition in acute myocardial infarction:the randomized monAMI trial[J].Circulation,2020,141(16):1354-1356. DOI:10.1161/CIRCULATIONAHA.119.042816.
• [46] Svilaas T, Vlaar PJ, van der Horst IC, et al. Thrombus aspiration during primary percutaneous coronary intervention[J].N Engl J Med, 2008, 358(6):557-567. DOI:10.1056/NEJMoa0706416.
• [47] Jolly SS, Cairns JA, Lavi S, et al. Thrombus aspiration in patients with high thrombus burden in the TOTAL trial[J].J Am Coll Cardiol, 2018, 72(14):1589-1596. DOI:10.1016/j.jacc.2018.07.047.
• [48] Jolly SS, James S, D?avík V, et al. Thrombus aspiration in ST-segment–elevation myocardial infarction:an individual patient Meta-analysis:thrombectomy trialists collaboration[J]. Circulation, 2017, 135(2):143-152. DOI:10.1161/CIRCULATIONAHA.116.025371.
• [49]刘金武，荣晶晶，刘征宇，等.血栓抽吸联合冠状动脉内溶栓对急性ST段抬高型心肌梗死患者直接经皮冠状动脉介入治疗术后冠状动脉微循环的影响[J].中国循环杂志，2022, 37(11):1097-1104. DOI:10.3969/j.issn.1000-3614.2022.11.004.
• [50] Hibi K, Kozuma K, Sonoda S, et al. A randomized study of distal filter protection versus conventional treatment during percutaneous coronary intervention in patients with attenuated plaque identified by intravascular ultrasound[J].JACC-Cardiovasc Intev, 2018, 11(16):1545-1555. DOI:10.1016/j.jcin.2018.03.021.
• [51] Hausenloy DJ, Kharbanda RK, M?ller UK, et al. Effect of remote ischaemic conditioning on clinical outcomes in patients with acute myocardial infarction(CONDI-2/ERIC-PPCI):a single-blind randomised controlled trial[J]. Lancet, 2019,394(10207):1415-1424. DOI:10.1016/S0140-6736(19)32039-2.
• [52] Li Q, Guo Z, Wu C, et al. Ischemia preconditioning alleviates ischemia/reperfusion injury-induced coronary no-reflow and contraction of microvascular pericytes in rats[J]. Microvasc Res, 2022, 142:104349. DOI:10.1016/j.mvr.2022.104349.
• [53] El Farissi M, Good R, Engstr?m T, et al. Safety of selective intracoronary hypothermia during primary percutaneous coronary intervention in patients with anterior STEMI[J]. JACCCardiovasc Intev, 2021, 14(18):2047-2055. DOI:10.1016/j.jcin.2021.06.009.
• [54] El Farissi M, Keulards DCJ, van’t Veer M, et al. Selective intracoronary hypothermia in patients with ST-elevation myocardial infarction. Rationale and design of the EURO-ICEtrial[J]. EuroIntervention, 2021, 16(17):1444-1446.DOI:10.4244/EIJ-D-19-00471.
• [55] Kumar R, Qayyum D, Ahmed I, et al. Predilation ballooning in high thrombus laden STEMIs:an independent predictor of slow flow/no-reflow in patients undergoing emergent percutaneous coronary revascularization[J]. J Interv Cardiol, 2023,2023:1-6. DOI:10.1155/2023/4012361.
• [56] Nepper-Christensen L, Kelb?k H, Ahtarovski KA, et al.Angiographic outcome in patients treated with deferred stenting after ST-segment elevation myocardial infarction—results from DANAMI-3-DEFER[J]. Euro Heart A J Acute Cardiovasc Care, 2022, 11(10):742-748. DOI:10.1093/ehjacc/zuac098.
• [57]崔冬，黄亚华，刘智坚，等.急性ST段抬高型心肌梗死经皮冠状动脉介入治疗术中采用球囊缓慢撤压方法预防无复流和慢血流现象的作用研究[J].中国介入心脏病学杂志，2022, 30(6):435-439.DOI:10.3969/j.issn.1004-8812.2022.06.008.
• [58] Ma M,Wang L,Diao KY, et al. A randomized controlled clinical trial of prolonged balloon inflation during stent deployment strategy in primary percutaneous coronary intervention for STsegment elevation myocardial infarction:a pilot study[J].BMC Cardiovasc Disord,2022,22(1):30. DOI:10.1186/s12872-022-02477-0.